Finally, when evaluating PST response, EANM-SNMMI state that [18F]FDG PET/CT may be used to assess early metabolic response, particularly for HER2+ BC and TNBC, and for whole body assessment at the end of PST. Here, ERBB2 is linked to breast cancer.